Understanding how BMP9 signaling affects lung transplant outcomes
Dissecting the role of vascular endothelial BMP9 signaling in lung transplantation
This study is looking at how a special protein called BMP9 might help improve lung transplant outcomes by reducing damage that can happen during the surgery, which affects many patients, and it hopes to find new ways to make lung transplants safer and more successful.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10996899 on NIH RePORTER |
What this research studies
This research investigates the role of bone morphogenetic protein 9 (BMP9) signaling in lung transplantation, particularly focusing on primary graft dysfunction (PGD), which affects 30% of lung transplant recipients. The study aims to understand how ischemia reperfusion injury (IRI) impacts lung microvasculature and contributes to PGD. By using both in vitro and in vivo models, the researchers will explore whether enhancing BMP9 signaling can mitigate the harmful effects of IRI and improve lung transplant outcomes. This could lead to new therapeutic strategies for patients undergoing lung transplantation.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are undergoing or have undergone lung transplantation and are at risk for primary graft dysfunction.
Not a fit: Patients who have not undergone lung transplantation or those with chronic lung diseases unrelated to transplant may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the survival and quality of life for lung transplant patients.
How similar studies have performed: While BMP signaling has been studied in other lung injuries, this specific investigation into its role in lung transplantation and PGD is novel and has not been previously tested.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Gill, Blake — Northwestern University at Chicago
- Study coordinator: Gill, Blake
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.